Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule.

Trial Profile

Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Axitinib (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Jun 2015 Results assessing pharmacodynamic presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 14 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top